Does pharmacologic reduction of Lp(a) concentration decrease CAD risk without increasing T2D risk?
Pharmacologic reduction of high Lp(a) to median levels is predicted to lower CAD risk without the adverse effect of increasing T2D risk seen at very low Lp(a) levels.
Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.
Guðbjartsson et al. (Sun,) studied this question.